Overview

Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

Status:
Completed
Trial end date:
2014-10-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of single doses of LAS190792 administered by inhalation to patients with mild persistent asthma and moderate to severe chronic obstructive pulmonary disease (COPD) and also to assess the ability of LAS190792 to produce bronchodilation (opening of the airways).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
LAS190792
Tiotropium Bromide